Updated: Sep 24
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
If you have reached the point where you are searching for cancer treatment in China from New Zealand, you may already have had difficult conversations with your oncologist. Perhaps a medicine is not publicly funded for your particular situation. Perhaps a treatment has stopped working. Or perhaps you simply want to know whether there is another specialist or treatment pathway worth investigating.
That does not automatically mean China is the right answer. It means there is another option worth assessing carefully.
New Zealand continues to expand access to cancer medicines. Pharmac decides which medicines and related products are funded, and its decisions are specific to particular conditions and eligibility criteria. In 2026, for example, Pharmac widened access to several treatments for chronic lymphocytic leukaemia, showing that the funded treatment landscape can change.
This guide explains what cancer treatment in China from New Zealand can actually involve, what treatments may be available, what you should expect to pay, how to verify a treatment and hospital, and what happens before and after the journey. For the broader treatment landscape, you can also read ChinaCureLink's Cancer Treatment in China: The Complete Guide for International Patients.
Key Takeaways |
|
Why Would a New Zealand Patient Consider Cancer Treatment in China?
The first question is not “Is China better?” It is more practical: is there a treatment or specialist pathway in China that is relevant to my particular cancer and not reasonably accessible to me in New Zealand?
New Zealand has a public cancer system and a national medicines-funding process through Pharmac. Health New Zealand says that Pharmac decides which medicines and related products are funded, while Health New Zealand provides cancer treatment and care throughout Aotearoa.
That system continues to evolve. Pharmac receives a large number of medicine funding applications and uses prioritisation processes to decide what can be funded. As of August 2026, Pharmac reported 159 applications on its Options for Investment list.
For some families, the issue is therefore not that treatment does not exist. The issue may be whether a particular medicine, cell therapy, procedure or clinical trial is accessible for their specific diagnosis at the time they need it.
China can sometimes provide another pathway to investigate.
The country has a large oncology system covering conventional cancer care as well as targeted medicines, immunotherapy, precision medicine, radiotherapy and cell-based treatments. ChinaCureLink's broader treatment guide describes these as separate treatment categories rather than one generic concept of “advanced cancer treatment”.
There is an important caveat: overseas treatment is not automatically better treatment. Travelling can add costs, physical stress, language barriers and continuity-of-care issues. The sensible first question is whether your specific case has a credible treatment pathway worth considering.
What cancer treatments are actually available in China?
The answer depends heavily on your cancer type, stage, biomarkers and previous treatment.
For some patients, the relevant treatment may be conventional surgery or radiation. For others, it may involve targeted therapy, immunotherapy, genomic testing or a cell-therapy programme.
Surgery, chemotherapy and radiotherapy
Chinese tertiary hospitals provide conventional oncology treatments including cancer surgery, chemotherapy and radiotherapy. More specialised radiation approaches, including particle therapy in selected centres, may also be relevant for particular tumours.
These treatments should still be assessed according to the same principles you would use at home: diagnosis, stage, pathology, imaging, treatment goals, expected benefit and risk.
Targeted therapy and precision medicine
If your tumour contains a specific molecular alteration, treatment may depend on the result of genomic or biomarker testing.
That makes your pathology report particularly important. A diagnosis such as “lung cancer” or “breast cancer” is not enough to determine whether a targeted treatment is appropriate.
Your records may need to include molecular results, immunohistochemistry, pathology slides or blocks, and the original imaging files.
Immunotherapy
Checkpoint inhibitors and other immunotherapies are used for a range of cancers. But immunotherapy is not one treatment and does not work for every patient.
The relevant drug, cancer type, biomarker status, previous treatments and overall health all matter. China has both domestically developed and internationally recognised immunotherapy medicines, but the regulatory indication and eligibility criteria should be checked for the exact drug and cancer.
CAR-T and other cell therapies
CAR-T therapy is one of the most specialised treatment areas available in China.
For blood cancers, several CAR-T products have been approved in China for specific indications. In 2026, China also approved satri-cel (CT041) for a specific group of patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma after specified prior treatment.
That is an important distinction. It does not mean that CAR-T is now available for all solid tumours.
CAR-T can also have serious complications, including cytokine release syndrome and neurological toxicity. Even when a product is approved, eligibility is highly specific and treatment requires specialist monitoring.
If you are considering CAR-T specifically, see the dedicated CAR-T Therapy in China for New Zealand Patients guide.
How much does cancer treatment in China cost?
There is no honest single figure for “cancer treatment in China”.
A short specialist consultation and imaging review are obviously very different financially from surgery, several cycles of systemic therapy or CAR-T treatment requiring prolonged hospital monitoring.
Your estimate can depend on:
the treatment itself
the medicine or cell-therapy product
hospital and specialist fees
pathology and genomic testing
imaging
inpatient stay
treatment-related complications
accommodation and travel
the length of time you need to remain in China
For CAR-T therapy, ChinaCureLink's standing figure is USD $100,000–$150,000 for total care. This should be treated as an indicative range, not a quotation. The actual cost depends on the diagnosis, product, hospital and clinical circumstances.
Other cancer treatments should not be presented as a blanket percentage cheaper than New Zealand, Australia or the United States without a treatment-specific comparison and source.
This is one reason an itemised estimate matters. A headline treatment price can look attractive until you discover that hospitalisation, diagnostic testing, medication or monitoring is separate.
A useful question to ask any medical facilitator is:
“What exactly is included in the quoted treatment cost, and what circumstances could make the final bill higher?”
ChinaCureLink's process is designed to provide a written treatment plan and itemised estimate before a patient makes a commitment to travel.
For a practical overview of the process, see How to Get Cancer Treatment in China: Step-by-Step Patient Guide.
How do I know the hospital and treatment are legitimate?
This is probably the most important question to ask before sending money or booking a flight.
Do not judge a cancer programme simply because a website calls a hospital “world-class”. Ask what regulator approved the treatment, what its exact indication is, who will administer it and whether the hospital has accepted your particular case.
For medicines and cell therapies, China's National Medical Products Administration (NMPA) is the relevant national regulator. But an NMPA approval still has a defined indication. Approval for one cancer does not automatically mean approval for another.
The same principle applies to clinical trials. A trial may be scientifically interesting but still not be appropriate for your diagnosis, treatment history, location or health status.
You should also verify the hospital itself. China uses a hospital classification system in which Grade 3A institutions represent the highest tier. However, a classification label alone does not tell you whether a particular department or doctor is appropriate for your cancer.
Before travelling, ask for:
The hospital's full legal name and department.
The treating specialist's name and credentials.
The treatment's regulatory status and exact indication.
Whether your case has been reviewed and accepted by the treating team.
A written treatment plan.
A written cost estimate.
The expected length of stay and monitoring requirements.
What records will be provided when treatment is completed.
Language is a genuine challenge. Medical translation is not simply translating ordinary conversation. Pathology, imaging, medication names and discharge instructions need to be accurate.
That is one point where a specialist medical concierge can be useful. ChinaCureLink coordinates record translation, hospital communication and professional medical interpretation so the family is not left to manage technical conversations alone.
What does travelling from New Zealand for cancer treatment actually involve?
Medical travel is more complicated than buying a plane ticket.
The process normally begins while you are still in New Zealand. Your medical records are collected and reviewed, the relevant treatment pathway is identified, and the hospital needs to assess whether it can accept the case.
Your records may include your discharge summaries, pathology reports, biopsy results, molecular testing, medication list and DICOM imaging files rather than just screenshots of scans.
Once a hospital has reviewed the case, the practical arrangements can begin. Depending on the treatment, these may include a hospital invitation or admission documentation, visa arrangements, flights, accommodation and airport transfers.
Visa rules require particular care. China does not have one universal visa category simply called a “medical visa”. The appropriate category and documentation depend on the patient's circumstances and the applicable policy. ChinaCureLink's China Medical Visa Guide 2026 explains why patients should confirm the appropriate category with the Chinese embassy, consulate or visa centre rather than assuming that a general visa-free policy covers medical treatment.
There is another practical issue that families sometimes underestimate: you may need to stay in China longer than the treatment day itself.
A consultation may be relatively quick. A cell therapy programme can require weeks of monitoring. Surgery may require recovery time before you are fit to fly.
If your treatment involves a serious risk of complications, you should also ask the treating team how long they want you to remain locally available after treatment.
What happens when I return to New Zealand?
Returning home should be part of the treatment plan from the beginning.
Before leaving China, ask for a complete medical record package that your New Zealand oncologist can understand. This may include the diagnosis and pathology, treatment dates, medicines and doses, imaging results, laboratory results, procedure notes, complications and follow-up recommendations.
For a patient continuing cancer care in New Zealand, this handover is clinically important. Your oncologist needs to know exactly what treatment you received before deciding what should happen next.
The ideal discharge package should therefore be more than a receipt or a short letter.
Ask for:
a translated discharge summary
pathology and laboratory reports
imaging reports and, where possible, the original imaging files
treatment and medication records
details of any adverse reactions or complications
the treating doctor's follow-up recommendations
contact information for the treating department where appropriate
ChinaCureLink can coordinate a translated discharge packet intended to make the handover to your home medical team more practical, along with follow-up support after you return.
There is still a limit: ChinaCureLink cannot replace your New Zealand oncologist. Your ongoing care after returning home needs to be agreed with your local medical team.
How do I find out whether treatment in China is suitable for my case?
You do not need to decide to travel before finding out whether there is a reasonable treatment pathway.
The first useful step is a case assessment.
A proper assessment should look at your diagnosis, pathology, stage, previous treatments, current disease status, biomarkers, imaging and general clinical condition. The purpose is not to promise that China has a solution. It is to establish whether there is a treatment or specialist pathway worth discussing.
If the answer is no, that is also useful information.
If there is a potential pathway, the next questions are more concrete: which hospital, which specialist, which treatment, what eligibility criteria, what risks, how long would you need to stay and what would it cost?
You can also use the same approach when speaking to any facilitator. Ask them to explain why they believe a particular treatment applies to your case, rather than accepting a generic list of treatments.
For patients who want to understand the process before making contact, ChinaCureLink's step-by-step cancer treatment guide walks through the case-review and hospital-matching process.
How ChinaCureLink Can Help New Zealand Patients with Cancer Treatment
If you are dealing with an unfunded treatment, uncertainty about whether another option exists, difficulty communicating with an overseas hospital, or the worry that you will return home without records your oncologist can use, the first step does not have to be a flight.
ChinaCureLink begins with a review of your medical records to understand whether your case may be suitable for treatment in China. The relevant hospital and specialist are matched to your diagnosis and treatment history rather than simply selected from a generic ranking list.
If there is a potential pathway, your records can be translated and a remote video consultation arranged before you travel. The treating team can then discuss the proposed treatment, eligibility, risks and expected process. Where appropriate, ChinaCureLink can coordinate a written treatment plan and itemised cost estimate before you make a commitment.
Once you decide to proceed, practical coordination can include visa documentation, flights, accommodation and airport transfers. A dedicated care manager and professional medical interpreters can support communication during the medical journey.
The process can also continue after treatment. A translated discharge packet can be prepared for your home oncologist, with follow-up coordination after you return to New Zealand.
The next step is an assessment, not a flight.
You are not committing to treatment simply by asking whether a pathway exists.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions
Is cancer treatment in China available for New Zealand patients?
Yes, international patients can seek cancer care in China, but availability depends on the diagnosis, treatment, eligibility criteria and the hospital's ability to accept the case. Some treatments are approved for specific indications, while others may be available only through clinical trials. A case review should come before travel.
How much does cancer treatment in China cost?
Costs vary significantly according to the cancer and treatment. Surgery, chemotherapy, radiotherapy, immunotherapy and cell therapy have very different cost structures. ChinaCureLink's standing figure for total CAR-T care is USD $100,000–$150,000. Other treatment costs should be confirmed through an itemised quotation for the individual case.
Does Pharmac fund cancer treatment received in China?
Pharmac's role is to decide which medicines and related products are publicly funded in New Zealand. Funding decisions apply to specific medicines, conditions and eligibility criteria. They do not mean that Pharmac will fund privately arranged treatment overseas. Patients should confirm any potential funding or reimbursement issue directly with the relevant New Zealand authority.
Is China safe for cancer treatment?
Safety depends on the treatment, hospital, treating team and the patient's medical condition. Families should verify the hospital, doctor's credentials, treatment approval, eligibility criteria, monitoring arrangements and emergency support before travelling. Cancer treatments such as CAR-T also carry significant medical risks and require specialist monitoring.
What medical records do I need to travel to China for cancer treatment?
Start with your pathology and biopsy reports, treatment history, medication list, blood-test results, discharge summaries and imaging. Ask for original DICOM imaging files rather than relying only on screenshots. Depending on the treatment, molecular or biomarker testing may also be required.
Do I need a medical visa to receive cancer treatment in China?
There is no single universal Chinese visa category called a “medical visa”. The appropriate entry permission depends on the patient's circumstances and the current rules. New Zealand patients should confirm the correct category and documentation with the relevant Chinese embassy, consulate or visa centre before travelling
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
Health New Zealand — Cancer treatments and access to funded cancer medicines.
Pharmac — Priority lists for funding applications.
Pharmac — Funding and widening access to treatments for chronic lymphocytic leukaemia, April 2026.
Health New Zealand / Cancer Control Agency — New Zealand Cancer Action Plan 2026–2029.
ChinaCureLink — Cancer Treatment in China: The Complete Guide for International Patients (2026).
ChinaCureLink — How to Get Cancer Treatment in China: Step-by-Step Patient Guide.
ChinaCureLink — China Medical Visa 2026.
ChinaCureLink — CAR-T Therapy in China for New Zealand Patients.
ChinaCureLink — Advanced Cancer Treatment in China.
ChinaCureLink — Gastric Cancer CAR-T in China: 2026 Access Guide.
